In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness expands with HemoSense deal

This article was originally published in Clinica

Executive Summary

Inverness Medical Innovations (Waltham, Massachusetts) has entered into a definitive agreement to purchase point-of-care diagnostic company HemoSense. The all-stock deal, which is subject to shareholder approval and is expected to close in the fourth quarter of 2007, will see each holder of a HemoSense share receive 0.274192 shares of Inverness common stock - an approximate 38% premium over the average trading prices of both companies for the last five trading days.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel